Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)

South Korea flag South Korea · Delayed Price · Currency is KRW
141,400
-100 (-0.07%)
Mar 3, 2026, 10:20 AM KST
385.08%
Market Cap 4.30T
Revenue (ttm) 7.75B
Net Income (ttm) -21.89B
Shares Out 30.37M
EPS (ttm) -728.12
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 44,785
Average Volume 234,187
Open 135,000
Previous Close 141,500
Day's Range 135,000 - 141,500
52-Week Range 25,450 - 179,900
Beta 1.37
RSI 54.92
Earnings Date Mar 19, 2026

About Mezzion Pharma

Mezzion Pharma Co.,Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company developing JURVIGO, which is in Phase 3 clinical trial for treatment option to improve the physiology and exercise capacity of Fontan patients 12 years and older. The company was formerly known as Dong-A Pharmtech Co., Ltd. and changed its name to Mezzion Pharma Co.,Ltd. in April 2013. Mezzion Pharma Co.,Ltd. was founded in 2002 and is headquartered in Seoul, South Korea. [Read more]

Industry Medical - Pharmaceuticals
Sector Healthcare
Founded 2002
Employees 18
Stock Exchange KOSDAQ
Ticker Symbol 140410
Full Company Profile

Financial Performance

In 2024, Mezzion Pharma's revenue was 8.61 billion, a decrease of -72.85% compared to the previous year's 31.72 billion. Losses were -19.48 billion, 53.0% more than in 2023.

Financial Statements

News

There is no news available yet.